Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids
- PMID: 10754457
- DOI: 10.1159/000029913
Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids
Abstract
The nonhalogenated double ester of prednisolone, prednicarbate (PC), is the first topical glucocorticoid with an improved benefit/risk ratio verified clinically and in vitro. To evaluate if this is due to unique characteristics of this steroid, a new compound created according to an identical concept, prednisolone 17-ethylcarbonate, 21-phenylacetate (PEP), and the new halogenated monoester desoximetasone 21-cinnamate (DCE) were tested and compared to PC, desoximetasone (DM) and betamethasone 17-valerate (BMV). Isolated foreskin keratinocytes served for in vitro investigations of anti-inflammatory processes in the epidermis, fibroblasts of the same origin were used to investigate the atrophogenic potential. Inflammation was induced by TNFalpha, resulting in an increased interleukin 1alpha (Il-1alpha) synthesis. As quantified by ELISA, all drugs significantly reduced Il-1alpha production. But PC and BMV appeared particularly potent, followed by DM and the two new congeners, which revealed minor anti-inflammatory activity. Glucocorticoid esters including PEP are rapidly degraded in keratinocytes (85% within 12 h). Hence, a ribonuclease protection assay of Il-1alpha mRNA was performed allowing short incubation times and thus minimizing biodegradation. This assay confirmed the anti-inflammatory potency of native PC and BMV. In contrary DCE and PEP did not reduce Il-1alpha mRNA to a significant extent. Therefore PEP acts as a prodrug only. In fibroblasts, Il-1alpha and Il-6 syntheses indicate proliferation and inflammation, respectively. Whereas PC and PEP inhibited Il-1alpha and Il-6 production in fibroblasts only to a minor extent, cytokine synthesis was strongly affected by the conventional glucocorticoids BMV and DM, but also by DCE. The minor unwanted effect of PC and PEP on fibroblasts was also reflected by their low influence on cell proliferation as derived from (3)H-thymidine incorporation. Again, more pronounced antiproliferative features were seen with the halogenated glucocorticoids. In the following, the correlation between antiphlogistic effects in keratinocytes (suppression of Il-1alpha) and antiproliferative effects in fibroblasts (suppression of Il-1alpha and Il-6; (3)H-thymidine incorporation) was analyzed. Here, PC is revealed as the only glucocorticoid with an improved benefit/risk ratio. Native PEP is shown to be almost ineffective and DCE presents exactly the opposite features of PC. It is tempting to speculate if this is due to different glucocorticoid receptor subtypes or different signaling pathways in keratinocytes and fibroblasts.
Copyright 2000 S. Karger AG, Basel.
Similar articles
-
Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro.Pharm Res. 1997 Dec;14(12):1744-9. doi: 10.1023/a:1012183914011. Pharm Res. 1997. PMID: 9453063
-
Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.Pharm Res. 1997 Jun;14(6):793-7. doi: 10.1023/a:1012162708675. Pharm Res. 1997. PMID: 9210199
-
Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin.Pharm Res. 1999 Sep;16(9):1386-91. doi: 10.1023/a:1018946924585. Pharm Res. 1999. PMID: 10496654
-
Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.Drug Saf. 1996 Jun;14(6):375-85. doi: 10.2165/00002018-199614060-00003. Drug Saf. 1996. PMID: 8828015 Review.
-
Prednicarbate (Dermatop): profile of a corticosteroid.J Cutan Med Surg. 2004 Jul-Aug;8(4):244-7. doi: 10.1007/s10227-004-0120-x. J Cutan Med Surg. 2004. PMID: 16092003 Review.
Cited by
-
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy.Lasers Med Sci. 2012 Sep;27(5):1059-65. doi: 10.1007/s10103-011-1045-4. Epub 2012 Jan 17. Lasers Med Sci. 2012. PMID: 22249456
-
A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients.Aesthet Surg J Open Forum. 2025 Apr 25;7:ojaf030. doi: 10.1093/asjof/ojaf030. eCollection 2025. Aesthet Surg J Open Forum. 2025. PMID: 40401118 Free PMC article.
-
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.Dermatol Ther (Heidelb). 2017 Sep;7(3):265-279. doi: 10.1007/s13555-017-0196-z. Epub 2017 Aug 7. Dermatol Ther (Heidelb). 2017. PMID: 28785924 Free PMC article. Review.
-
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy.Dermatoendocrinol. 2011 Jul;3(3):175-9. doi: 10.4161/derm.3.3.15065. Epub 2011 Jul 1. Dermatoendocrinol. 2011. PMID: 22110776 Free PMC article.
-
Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.Clin Drug Investig. 2006;26(4):227-33. doi: 10.2165/00044011-200626040-00008. Clin Drug Investig. 2006. PMID: 17163256 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous